Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cambridge Peptides was a UK-based contract research organization specializing in the custom synthesis of peptides for pharmaceutical and biotechnological applications. The company provided a wide range of services, including the production of modified peptides, peptide libraries, and specialty reagents for research and clinical development. It was recognized for its expertise in complex peptide chemistry, including fluorescent labeling and stable isotope incorporation. In October 2007, Cambridge Peptides was acquired by the Almac Group, a global contract development and manufacturing organization. This acquisition allowed Almac to significantly expand its peptide synthesis capabilities and integrate Cambridge Peptides' technical expertise into its Almac Sciences division. The company's operations were subsequently merged into Almac's broader service portfolio, supporting drug discovery programs worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cambridge Peptides.